SPOTLIGHT -
Synthetic Lethality of PARP Inhibitors in Prostate Cancer
In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.